(NASDAQ: VOR) Vor Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.8%.
Vor Biopharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast VOR's revenue for 2025 to be $686,736,120, with the lowest VOR revenue forecast at $686,736,120, and the highest VOR revenue forecast at $686,736,120. On average, 1 Wall Street analysts forecast VOR's revenue for 2026 to be $3,433,680,600, with the lowest VOR revenue forecast at $3,433,680,600, and the highest VOR revenue forecast at $3,433,680,600.
In 2027, VOR is forecast to generate $3,571,920,581 in revenue, with the lowest revenue forecast at $599,520,633 and the highest revenue forecast at $6,682,629,184.